“Non-Cystic Fibrosis Bronchiectasis Epidemiology” report has been added to DelveInsight

 

Overview of Non-Cystic Fibrosis Bronchiectasis epidemiology report, pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies

 

Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-epidemiology-forecast

 

Non-Cystic Fibrosis Bronchiectasis Overview

Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.

 

Non-Cystic Fibrosis Bronchiectasis: Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Non-Cystic Fibrosis Bronchiectasis Prevalence

Prevalence of NCFB is reported to be higher in females. The prevalence of NCFB vary among populations, but studies report an overall prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.

 

Non-Cystic Fibrosis Bronchiectasis Epidemiology Insights

NCFB results in irreversible changes in the bronchial walls which may occur due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified. Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum.

 

Important key facts of Non-cystic Fibrosis Bronchiectasis Market Report

• As per DelveInsight’s estimates, in 2018, prevalence of Non–cystic fibrosis bronchiectasis was estimated to be 812,266 in the 7MM.
• DelveInsight’s assessment suggests that United State accounted for most prevalent cases of Non–cystic fibrosis bronchiectasis among 7MM with 447,083 cases in 2018.
• Among EU5 countries, Germany had the highest number of prevalent cases of Non–cystic fibrosis bronchiectasis accounting for 45,651 cases in 2018.
• According to the study conducted by McShane et al., titled “Non-Cystic Fibrosis Bronchiectasis”, the prevalence of bronchiectasis is increasing in the United States. The prevalence increased every year from 2000 to 2007 by an annual percentage change of 8%. Prevalence was also shown to increase with age and peaked at ages 80–84 years.

 

Non-cystic Fibrosis Bronchiectasis Epidemiology Segmentation

• Prevalent Population of NCFB in 7MM (2018–2030)
• Diagnosed Population of NCFB in 7MM (2018–2030)
• Gender Specific Diagnosed Prevalence of NCFB in 7MM (2018–2030)
• Severity Specific Diagnosed prevalence NCFB in 7MM (2018–2030)
• Etiology associated with NCFB in 7MM (2018–2030)
• Microbiology of NCFB patients in 7MM (2018–2030)

 

Non-cystic Fibrosis Bronchiectasis Report Highlights

• 11-Year Forecast of Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology
• 7MM Coverage
• Total Cases of Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Total Cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) according to segmentation
• Diagnosed cases of Non-Cystic Fibrosis Bronchiectasis (NCFB)

 

Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-epidemiology-forecast

 

Following is the TOC of Non-cystic Fibrosis Bronchiectasis report

1. Key Insights 

2. Executive Summary of Non-Cystic Fibrosis Bronchiectasis (NCFB)

3. Non-Cystic Fibrosis Bronchiectasis (NCFB): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Why should you buy this report?

• Develop business strategies by understanding the trends shaping and driving the global Non-Cystic Fibrosis Bronchiectasis (NCFB) market
• Quantify patient populations in the global Non-Cystic Fibrosis Bronchiectasis (NCFB) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutics in each of the markets covered
• Understand the magnitude of Non-Cystic Fibrosis Bronchiectasis (NCFB) population by its epidemiology
• The Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

Non-Cystic Fibrosis Bronchiectasis Market

DelveInsight’s Non-Cystic Fibrosis Bronchiectasis (NCFB) – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth

Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/